Log in

Relevant bibliographies by topics / Mianserina / Journal articles

To see the other types of publications on this topic, follow the link: Mianserina.

Journal articles on the topic 'Mianserina'

Author: Grafiati

Published: 4 June 2021

Last updated: 15 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Mianserina.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Jolliet, P., G. Veyrac, and M. Bourin. "Primer informe de artralgia inducida por mirtazapina." European psychiatry (Ed. Española) 9, no. 3 (April 2002): 190–92. http://dx.doi.org/10.1017/s1134066500007359.

Full text

Abstract:

ResumenObjetivo:El propósito de nuestro trabajo es describir los dos primeros casos de artralgia asociada con el medicamento antidepresivo mirtazapina.Método:Análisis descriptivo de dos casos yatrogánicos. La revisión de las publicaciones se llevó a cabo por los métodos electrónicos tradicionales. Se consultó la base de datos francesa de casos yatrogénicos.Resultados:Un hombre de 53 años acudio con gonalgia después de algunas semanas de tratamiento con mirtazapina. La intensidad de la artralgia correlacionaba con la dosis y el efecto adverso desapareció rápidamente después de la interruptión de la terapia antidepresiva. Una mujer de 38 años recibió mirtazapina durante 3 meses y se quejó de artralgia y mialgia. Este cuadro clínico se suspendió cuando el medicamento se interrumpió y se observó una nueva introductión positiva. No se encontró otra causa en estos dos pacientes.Discusión:No se ha comunicado ningún caso similar en las publicaciones intemacionales, pero se mencionan varias observaciones de artralgia con mianserina. Como la mirtazapina es el derivado 6-aza del antidepresivo tetracíclico mianserina, la similitud de sus estructuras químicas permite pensar la responsabilidad de la artralgia para la mirtazapina.

APA, Harvard, Vancouver, ISO, and other styles

2

Müller, H., and H. J. Möller. "Un enfoque de análisis de regresión para estimar el comienzo de la actividad de los antidepresivos." European psychiatry (Ed. Española) 5, no. 7 (October 1998): 446–48. http://dx.doi.org/10.1017/s1134066500002435.

Full text

Abstract:

ResumenEl comienzo de la actividad de los antidepresivos es un criterio de eficacia importante clínica y teórica mente. Estimamos el comienzo de la actividad por un enfoque de análisis de regresión intraindividual. Se supone que el tratamiento eficiente causa un cambio rápido de las puntuaciones de depresión desde un nivel de línea de base a un nivel final. De este supuesto se deriva un número limitado de oportunidades para que se produzca el comienzo de la actividad. Estas oportunidades corresponden a modelos de regresión diferentes que se estiman para el curso de la depresión de cada paciente. El día de comienzo se concluye a partir del modelo de regresión que produce el mejor ajuste a la curva de depresión empírica. Se comunican los resultados de un ensayo clínico doble ciego que comparó la mianserina y la amitriptilina (n = 28). El enfoque metodológico confirma que las estimaciones realizadas por los médicos muestran un comienzo significativamente más temprano de la actividad que las autoevaluaciones de los propios pacien tes. La D-S muestra también un comienzo de la actividad significativamente anterior de la mianserina en comparación con la amitriptilina. La discusión pone de relieve los aspectos metodológicos.

APA, Harvard, Vancouver, ISO, and other styles

3

Lauge, N., K. Behnke, J. Søgaard, B. Bahr, and P. Bech. "Sensibilidad de las escalas de evaluación del observador por el análisis del número de días hasta la mejoría en pacientes con depresión mayor." European psychiatry (Ed. Española) 5, no. 7 (October 1998): 451–54. http://dx.doi.org/10.1017/s1134066500002447.

Full text

Abstract:

ResumenVarias escalas del observador muy conocidas, incluidas la Escala de Valoración Psiquiátrica de Hamilton para la Depresión (HAM-D), la Escala de Evaluación de la Depresión de Montgomery y Åsberg (MADRS), la Escala de Evaluación de la Depresión Mayor (MDS), la Escala de Melancolía (MES) y el Inventario para Síntomas Depresivos (IDS), utilizadas para medir la gravedad de los estados depresivos, se han comparado con arreglo a su sensibilidad en un ensayo abierto que incluía a pacientes tratados con una combinación de citalopram y mianserina. Los pacientes cumplían los criterios del Manual Diagnóstico y Estadístico (DSM)-IV para episodio depresivo mayor y todos puntuaban 18 o más en la HAM-D antes del tratamiento. El comienzo de la acción antidepresiva se definió como una mejoría en las puntuaciones de la escala de evaluación del 25% o más de las puntuaciones previas al tratamiento. Una respuesta al tratamiento se definió como una reducción de 50% o más en las puntuaciones previas. Los resultados mostraron que el número de días de tratamiento hasta la mejoría fue de 11 a 13, sin diferencia entre las escalas. Los días hasta la respuesta fueron entre 18 y 21, sin diferencia entre las escalas. En conclusión, se encontró que las escalas de depresión eran iguales en cuanto a su capacidad para detectar cambios en los síntomas depresivos durante el tratamiento. La media de días hasta la respuesta fue 19 para la combinación de citalopram y mianserina. Esta respuesta es similar a la obtenida para la combinación de fluoxetina y pinolol.

APA, Harvard, Vancouver, ISO, and other styles

4

Stryjer, Rafael, Daniel Grupper, Rael Strous, Michael Poyurovsky, and Abraham Weizman. "Mianserina para la mejoría rápida de la acatisia crónica en un paciente esquizofrénico." European psychiatry (Ed. Española) 11, no. 7 (October 2004): 459–60. http://dx.doi.org/10.1017/s1134066500004914.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Otani, Koichi, Sunao Kaneko, Yutaka Fukushima, and Shuji Kubota. "Involuntary Movements Associated with Mianserin Treatment." British Journal of Psychiatry 154, no. 1 (January 1989): 113–14. http://dx.doi.org/10.1192/bjp.154.1.113.

Full text

Abstract:

A case showing various involuntary movements during mianserin treatment and after a withdrawal of mianserin is described. This is the first case report of mianserin-induced involuntary movements. The report suggests that these symptoms can occur with a therapeutic dose of mianserin in certain susceptible patients.

APA, Harvard, Vancouver, ISO, and other styles

6

Carcone, Bernard, Thierry Vial, Nicolas Chaillet, and Jacques Descotes. "Symptomatic Bradycardia Caused by Mianserin at Therapeutic Doses." Human & Experimental Toxicology 10, no. 5 (September 1991): 383–84. http://dx.doi.org/10.1177/096032719101000514.

Full text

Abstract:

An acute episode of symptomatic sinus bradycardia, occurred in a 50-year-old female patient after she had been given a single therapeutic dose of mianserin. Heart rate was corrected by atropine injection. Re-administration of mianserin resulted in the recurrence of bradycardia. Further examination showed no cardiac abnormalities. This case is the first report of conduction defect in a patient given therapeutic doses of mianserin.

APA, Harvard, Vancouver, ISO, and other styles

7

&NA;. "Mianserin." Reactions Weekly &NA;, no. 1319 (September 2010): 34. http://dx.doi.org/10.2165/00128415-201013190-00120.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Mianserin." Reactions Weekly &NA;, no. 1310 (July 2010): 34. http://dx.doi.org/10.2165/00128415-201013100-00112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

&NA;. "Mianserin." Reactions Weekly &NA;, no. 469 (September 1993): 9. http://dx.doi.org/10.2165/00128415-199304690-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

&NA;. "Mianserin." Reactions Weekly &NA;, no. 322 (October 1990): 10. http://dx.doi.org/10.2165/00128415-199003220-00039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

&NA;. "Mianserin." Reactions Weekly &NA;, no. 324 (October 1990): 6. http://dx.doi.org/10.2165/00128415-199003240-00026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

&NA;. "Mianserin." Reactions Weekly &NA;, no. 325 (November 1990): 10. http://dx.doi.org/10.2165/00128415-199003250-00047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

&NA;. "Mianserin." Reactions Weekly &NA;, no. 332 (December 1990): 7. http://dx.doi.org/10.2165/00128415-199003320-00032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Mianserin." Reactions Weekly &NA;, no. 333 (January 1991): 9. http://dx.doi.org/10.2165/00128415-199103330-00049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Mianserin." Reactions Weekly &NA;, no. 344 (March 1991): 9. http://dx.doi.org/10.2165/00128415-199103440-00035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

&NA;. "Mianserin." Reactions Weekly &NA;, no. 349 (May 1991): 10. http://dx.doi.org/10.2165/00128415-199103490-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Mianserin." Reactions Weekly &NA;, no. 352 (May 1991): 8. http://dx.doi.org/10.2165/00128415-199103520-00050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Mianserin." Reactions Weekly &NA;, no. 587 (February 1996): 6. http://dx.doi.org/10.2165/00128415-199605870-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Mianserin." Reactions Weekly &NA;, no. 480 (December 1993): 9. http://dx.doi.org/10.2165/00128415-199304800-00036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

&NA;. "Mianserin." Reactions Weekly &NA;, no. 482 (December 1993): 10. http://dx.doi.org/10.2165/00128415-199304820-00047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

&NA;. "Mianserin." Reactions Weekly &NA;, no. 613 (August 1996): 10. http://dx.doi.org/10.2165/00128415-199606130-00030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Mianserin." Reactions Weekly &NA;, no. 653 (May 1997): 9. http://dx.doi.org/10.2165/00128415-199706530-00026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Mianserin." Reactions Weekly &NA;, no. 1166 (August 2007): 17. http://dx.doi.org/10.2165/00128415-200711660-00055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Mianserin." Reactions Weekly &NA;, no. 1134 (January 2007): 19. http://dx.doi.org/10.2165/00128415-200711340-00063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Mianserin." Reactions Weekly &NA;, no. 1141 (March 2007): 17. http://dx.doi.org/10.2165/00128415-200711410-00063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Medawar, Charles, Elaine Rassaby, and Andrew Herxheimer. "MIANSERIN." Lancet 333, no. 8631 (January 1989): 220. http://dx.doi.org/10.1016/s0140-6736(89)91236-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Inman, WilliamH W., Charles Medawar, Elaine Rassaby, Andrew Herxheimer, Etsuro Totsuka, and SamuelI Cohen. "MIANSERIN." Lancet 333, no. 8634 (February 1989): 382. http://dx.doi.org/10.1016/s0140-6736(89)91752-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Mianserin." Reactions Weekly &NA;, no. 396 (April 1992): 7. http://dx.doi.org/10.2165/00128415-199203960-00026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

&NA;. "Mianserin." Reactions Weekly &NA;, no. 367 (September 1991): 10. http://dx.doi.org/10.2165/00128415-199103670-00050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Mianserin." Reactions Weekly &NA;, no. 371 (October 1991): 10. http://dx.doi.org/10.2165/00128415-199103710-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Koseoglu, Zikret, Banu Kara, and Salim Satar. "Bradycardia and hypotension in mianserin intoxication." Human & Experimental Toxicology 29, no. 10 (March 4, 2010): 887–88. http://dx.doi.org/10.1177/0960327110364639.

Full text

Abstract:

Cardiotoxicity is an important adverse effect of tricyclic antidepressants. But cardiac side effects after intoxication with the tetracyclic mianserin are rare. In this paper, we describe a case in which bradycardia and hypotension occured due to mianserin overdose. A 37-year-old woman was admitted to the medical intensive care unit for self-poisoning with 30 tablets of 10 mg mianserin 2 hours before her admission. The patient denied taking any other drugs. Four hours after her admission, bradycardia and hypotension occurred and she began to suffer from giddiness. Atropine and theophylline were given. On the second and third day, her heart rate and blood pressure were normal. Based on this case, we estimate the probability of bradycardia and hypotension in mianserin intoxication and the significance of closely monitoring the patient.

APA, Harvard, Vancouver, ISO, and other styles

32

Hla, K. K., and O. Boyd. "Mianserin and Complete Heart Block." Human Toxicology 6, no. 5 (September 1987): 401–2. http://dx.doi.org/10.1177/096032718700600510.

Full text

Abstract:

Cardiac complications are common in tricyclic antidepressant poisoning, but are rare with overdose of mianserin, which is a tetracyclic antidepressant. We report a case in which repeated episodes of complete heart block occurred following overdose with mianserin.

APA, Harvard, Vancouver, ISO, and other styles

33

Van Heeringen, Kees, and Milana Zivkov. "Pharmacological Treatment of Depression in Cancer Patients." British Journal of Psychiatry 169, no. 4 (October 1996): 440–43. http://dx.doi.org/10.1192/bjp.169.4.440.

Full text

Abstract:

BackgroundDepression has a reported mean prevalence of 24% in patients diagnosed with cancer. However, little systematic research on the efficacy of antidepressants in patients with cancer has been performed.MethodThe efficacy and safety of mianserin were studied in 55 depressed women with breast cancer (stage I or II and without known metastases), in a randomised, double-blind, six-week, placebo-controlled study.ResultsStatistically significant differences in the decrease in score from baseline on the Hamilton Rating Scale for Depression and the number of responders, favouring mianserin, were present after 28 and 42 days of treatment Significantly more placebo-treated patients prematurely terminated the study due to lack of efficacy while the safety profile of mianserin was similar to that of placebo.ConclusionsTreatment with mianserin resulted in a significant improvement in depressive symptoms in cancer patients, and was well tolerated.

APA, Harvard, Vancouver, ISO, and other styles

34

Naylor, G. J., and B. Martin. "A Double-Blind Out-Patient Trial of Indalpine vs Mianserin." British Journal of Psychiatry 147, no. 3 (September 1985): 306–9. http://dx.doi.org/10.1192/bjp.147.3.306.

Full text

Abstract:

SummaryIndalpine 150 mg per day and mianserin 60 mg per day were compared in a double-blind study of 65 depressed out-patients: 52 patients completed the 4-week trial. At the end of four weeks there was no significant difference in antidepressant effect between the two drugs; but in the first two weeks, improvement in the mianserin-treated group was significantly greater than that in the indalpine group. The mianserin-treated group reported more side-effects of sedation (eg. drowsiness, clumsiness, heaviness of limbs etc.) and one patient on indalpine developed a mild leucopenia.

APA, Harvard, Vancouver, ISO, and other styles

35

Theret, L., F. Bertholon, and MC Germain. "Two cases of mianserin abuse in psychiatric out-patients." European Psychiatry 7, no. 3 (1992): 143–44. http://dx.doi.org/10.1017/s0924933800003096.

Full text

Abstract:

SummaryTwo clinical observations of mianserin abuse by psychiatric out-patients are described. A previous history of substance dependence was found in both cases. Mianserin should be used with caution in predisposed patients, before further studies on the subject are carried out.

APA, Harvard, Vancouver, ISO, and other styles

36

Poyurovsky, Michael, Marina Shardorodsky, Camil Fuchs, Michael Schneidman, and Abraham Weizman. "Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin." British Journal of Psychiatry 174, no. 3 (March 1999): 238–42. http://dx.doi.org/10.1192/bjp.174.3.238.

Full text

Abstract:

BackgroundSerotonin (5-HT): dopamine imbalance may underlie neuroleptic-induced akathisia.AimTo evaluate the efficacy of the 5-HT2 antagonist, mianserin in neuroleptic-induced akathisia.MethodsThirty neuroleptic-treated patients with schizophrenia were randomly allocated in a double-blind design to receive either mianserin (15 mg/day) or placebo for five days. Patients were assessed at baseline and on Days 3 and 5 by the Barnes Akathisia Scale (BARS), as well as by other relevant clinical rating scales.ResultsCompared with the placebo group, the mianserin-treated patients showed a significant reduction in all four BARS subscales by Day 5, with mean reductions in the BARS global score of 9.9% and 52.2%, respectively (P=0.006). Response to treatment (a reduction of at least two points on the BARS global subscale), was noted in six patients (40%) in the mianserin group and only one patient (9.1%) in the placebo group (P=0.04, log odds ratio 2.23).ConclusionsMianserin at a low dose may be a promising therapeutic option for patients with acute neuroleptic-induced akathisia.

APA, Harvard, Vancouver, ISO, and other styles

37

Gondová, Tatána, and Iveta Petríková. "Determination of New Antidepressants in Pharmaceuticals by Thin-Layer Chromatography with Densitometry." Journal of AOAC INTERNATIONAL 93, no. 3 (May 1, 2010): 778–82. http://dx.doi.org/10.1093/jaoac/93.3.778.

Full text

Abstract:

Abstract A new and simple TLC-densitometry method has been developed for the simultaneous separation of the two noradrenergic and specific serotonergic antidepressants mirtazapine and mianserine and validated for their determination in commercially available tablets. The method used TLC plates precoated with silica gel 60F254 as the stationary phase, and the mobile phase consisted of hexaneisopropanol25 ammonia (70 + 25 + 5, v/v/v). Densitometric analysis was carried out in the absorbance mode at 280 nm. The method was validated in accordance with International Conference on Harmonization guidelines in terms of linearity, LOD, LOQ, precision, and accuracy. Calibration curves were linear (R2 > 0.9970) with respect to peak area in the concentration range of 5002500 and 5005000 ng/spot for mirtazapine and mianserine, respectively. The LODs were 20 and 35 ng/spot for mirtazapine and mianserine, respectively. The described method was successfully applied to the determination of mirtazapine and mianserine in their pharmaceutical formulations with recovery ranging from 99.83 to 101.20 of the labeled amount of the compounds. The proposed method can be used in routine QC of these drugs in pharmaceutical formulations.

APA, Harvard, Vancouver, ISO, and other styles

38

&NA;. "Mianserin/pravastatin." Reactions Weekly &NA;, no. 770 (September 1999): 7–8. http://dx.doi.org/10.2165/00128415-199907700-00023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "Mianserin withdrawal." Reactions Weekly &NA;, no. 283 (January 1990): 7. http://dx.doi.org/10.2165/00128415-199002830-00026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

&NA;. "Mianserin/venlafaxine." Reactions Weekly &NA;, no. 813 (August 2000): 8. http://dx.doi.org/10.2165/00128415-200008130-00022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Mianserin overdose." Reactions Weekly &NA;, no. 341 (March 1991): 8–9. http://dx.doi.org/10.2165/00128415-199103410-00048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

&NA;. "Mianserin/trazodone." Reactions Weekly &NA;, no. 586 (February 1996): 8. http://dx.doi.org/10.2165/00128415-199605860-00031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "Mianserin interaction." Reactions Weekly &NA;, no. 506 (June 1994): 9. http://dx.doi.org/10.2165/00128415-199405060-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "Mianserin overdose." Reactions Weekly &NA;, no. 1335 (January 2011): 31. http://dx.doi.org/10.2165/00128415-201113350-00112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

&NA;. "Mianserin/oxitriptan." Reactions Weekly &NA;, no. 416 (August 1992): 10. http://dx.doi.org/10.2165/00128415-199204160-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Wheatley, David. "Minaprine: An Anticholinergic-Free Antidepressant?" British Journal of Psychiatry 155, no. 1 (July 1989): 106–7. http://dx.doi.org/10.1192/bjp.155.1.106.

Full text

Abstract:

Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of anticholinergic effects, cardiotoxicity, drowsiness, and weight gain. Minaprine (100mg t.d.s. and 100mg b.d.) was compared with mianserin (20 mg t.d.s.) in 117 depressed patients, and all three regimes produced significant reductions in scores on the HRSD at the end of six weeks' treatment. There were no anticholinergic effects, but there was a significantly greater incidence of drowsiness with mianserin than with minaprine.

APA, Harvard, Vancouver, ISO, and other styles

47

&NA;. "Aripiprazole/mianserin/prednisolone." Reactions Weekly &NA;, no. 1224 (October 2008): 7. http://dx.doi.org/10.2165/00128415-200812240-00018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

&NA;. "Amitriptyline/mianserin/sulpiride." Reactions Weekly &NA;, no. 491 (March 1994): 4. http://dx.doi.org/10.2165/00128415-199404910-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

&NA;. "Amoxapine/mianserin/trazodone." Reactions Weekly &NA;, no. 974 (October 2003): 6. http://dx.doi.org/10.2165/00128415-200309740-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Inman, W. H. W. "SAFETY OF MIANSERIN." Lancet 332, no. 8612 (September 1988): 683–84. http://dx.doi.org/10.1016/s0140-6736(88)90493-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!